Early and clinically meaningful functional improvement following CGRP monoclonal antibodies in adolescents with migraine: A real-world retrospective study.

CGRP monoclonal antibodies (mAb) could help adolescents with migraines. This study focused on adolescents aged 15-17 years who received CGRP mAb therapy for migraine. It evaluated early functional outcomes in daily activities and headaches. The results showed that 33 out of 34 adolescents participated in the analyses. After treatment began, the response rate rose to 68% within 10-14 weeks. Notably, about half of the responders felt meaningful improvement by weeks 4-6. The average decrease in HIT-6 scores after 12 weeks was 9 points. School attendance and concentration were affected in 70% of participants before treatment. After therapy, 89% felt their treatment goals were achieved. However, 41% reported adverse events, primarily injection-site reactions. Importantly, none required therapy changes or discontinuations. Overall, CGRP mAb therapy showed promise for early functional improvements in adolescents with migraines. Clinical relevance: This research suggests that CGRP mAb therapy may significantly improve adolescent migraine management and daily functioning.